Answers are grounded in this paper and cite their sources.
Observational studies demonstrate improved management of asthma attacks in patients through precision medicine, suggesting reduced OCS use and better outcomes.
Recent studies have highlighted the heterogeneity of asthma attacks across clinical, etiological, and therapeutic dimensions. Biomarker-informed assessments using blood eosinophils, exhaled nitric oxide (FeNO), and point-of-care microbial molecular testing have improved the evaluation of attacks. Observational studies and trials have explored biomarker-guided management to reduce OCS and antibiotic use, potentially improving outcomes. Distinct inflammatory and OCS-response profiles were identified in patients on biologics, emphasizing the complexity of attacks and the importance of residual (untreated) type-2 inflammatory pathways. Studies on the airway microbiome revealed that microbial dysbiosis is associated with clinical and inflammatory clusters.
No takes yet. Share an insight, caveat, or question.
Preciado et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: